



UNITED STATES PATENT AND TRADEMARK OFFICE

Un.
Addr

P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

DEPARTMENT OF COMMERCE
Patent and Trademark Office
FOR PATENTS

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

09/955,656

09/18/2001

Charles A. Nicolette

GZ 2096.00

1157

30089

7590

06/04/2004

GENZYME CORPORATION C/O BINGHAM MCCUTCHEN
BINGHAM MCCUTCHEN, LLP
SAN FRANCISCO, CA 94111

EXAMINER

MYERS, CARLA J

ART UNIT

PAPER NUMBER

1634

DATE MAILED: 06/04/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/955,656

Applicant(s)

NICOLETTE ET AL.

Examiner

Carla Myers

Art Unit

1634

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 29 March 2004.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-10 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-10 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

1. This action is in response to the amendment filed March 29, 2004. Claims 1-10 are pending. Applicant's arguments and amendments have been fully considered but are not persuasive to overcome all grounds of rejection. All rejections not reiterated herein are hereby withdrawn. This action is made final.

Claim Rejections - 35 USC § 102

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-9 are rejected under 35 U.S.C. 102(b) as being anticipated by Mazzara et al for the reasons set forth in the Office action of September 29, 2003.

RESPONSE TO ARGUMENTS:

In the response of March 29, 2004, Applicants traversed this rejection by stating that the rejection has been rendered moot by the amendment to claim 1. In particular, it is asserted that the claim has been amended to clarify that the serum antibody required by the instant invention is obtained from a subject having the phenotype of interest. Applicant's assert that Mazzara does not teach or suggest this limitation.

Applicants arguments and amendments have been fully considered but are not persuasive to overcome the present grounds of rejection. The present claims require performing a single step in which one identifies a polypeptide. As written, the claims require that the polypeptide correlates with a phenotype of interest and that the

polypeptide recognizes and binds to a serum antibody from a subject. Mazzara does in fact teach each of these limitations. The method of Mazzara (see, for example, column 19) includes a step of detecting a polypeptide by reacting the polypeptide with human anti-HIV antiserum. It is thereby a property of the polypeptide detected in the method of Mazzara that this polypeptide would be capable of recognizing and binding to a serum antibody from a patient. It is also considered to be a property of this polypeptide that it is characteristic of a phenotype. The term "phenotype" is very broad and includes any number of parameters. For instance, the phenotype may be that an individual is HIV positive. Accordingly, in the method of Mazzara, the polypeptide is considered to "correlate with a phenotype of interest." It is further noted that the present claims do not require performing a step in which the polypeptide is reacted with serum antibody from a "subject having the phenotype of interest" as is argued by Applicants at page 5 of the response. Rather, the claims require only identifying a polypeptide that correlates with a phenotype of interest wherein the polypeptide binds with "a serum antibody obtained from a subject."

Claim Rejections - 35 USC § 103

3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claim 10 is rejected under 35 U.S.C. 103(a) as being unpatentable over Mazzara, as applied to claims 1-9 above, and further in view of Greenspan, for the reasons set forth in the Office action of September 29, 2003.

RESPONSE TO ARGUMENTS:

In the response of March 29, 2004, Applicants traversed this rejection for the same reasons as those set forth for claims 1-9 above. Accordingly, the response to those arguments set forth in paragraph 2 above apply equally to the present grounds of rejection.

THE FOLLOWING ARE NEW GROUNDS OF REJECTION NECESSITATED BY APPLICANTS AMENDMENTS TO THE CLAIMS:

Claim Rejections - 35 USC § 112

4. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-10 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 1-10 are indefinite over the recitation of "polypeptide correlating with a phenotype of interest, wherein the polypeptide specifically recognizes and binds a serum antibody obtained from a subject common to a list of characterized genes" because it is not clear as to whether it is the polypeptide, the antibody or the subject that is "common to a list of characterized genes." Given the structural and functional distinctions between polypeptides, antibodies and subjects and a "list of characterized

genes", it is unclear as to how a polypeptide, antibody or subject would be "common to a list of characterized genes." Accordingly, it is unclear as to how the recitation of "common to a list of characterized genes" further limits the claimed invention.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Carla Myers whose telephone number is (571) 272-0747. The examiner can normally be reached on Monday-Thursday from 6:30 AM-5:00 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion, can be reached on (571)-272-0782.

Papers related to this application may be faxed to Group 1634 via the PTO Fax Center using the fax number (703)-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For

Application/Control Number: 09/955,656

Page 6

Art Unit: 1634

more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Carla Myers
June 1, 2004


CARLA J. MYERS
PRIMARY EXAMINER

161000

HEMISEN

Organization U. S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231
IF UNDELIVERABLE RETURN IN TEN DAYS

OFFICIAL BUSINESS

AN EQUAL OPPORTUNITY EMPLOYER

REASON FOR RETURN
Undeliverable address
No such person or organization
No such office
Postage due

U.S. POSTAGE
\$40.83
JUL 13 2004

RECEIVED

JUL 02 2004

TECH CENTER 1000/2900

